Lung cancer vaccine - Northwest Biotherapeutics
Alternative Names: DCVax-LB; DCVax-LungLatest Information Update: 02 Oct 2021
At a glance
- Originator Northwest Biotherapeutics
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Glioblastoma
- No development reported Lung cancer
Most Recent Events
- 09 Aug 2019 Jonsson Comprehensive Cancer Center and National Cancer Institute withdraw a phase II trial for Glioblastoma (Combination therapy, Recurrent) in USA prior to enrolment (Parenteral) (NCT03014804)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lung-cancer in USA (Parenteral, Injection)
- 05 Jan 2017 Jonsson Comprehensive Cancer Center and National Cancer Institute plan a phase II trial for Glioblastoma (Combination therapy, Recurrent) in USA (Parenteral) (NCT03014804)